XYDALBA 500 mg, powder for concentrate for infusion bottle
Active ingredients: Dalbavancin hydrochloride, Dalbavancin
Commercialized according to BDPMDispensing in France: Prescription only
Powder for concentrate for infusionbottleintraveineuse
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- XYDALBA 500 mg, poudre pour solution à diluer pour perfusion
- Pharmaceutical form
- poudre pour solution à diluer pour perfusion
- Route of administration
- intraveineuse
- Presentation description
- flacon(s) en verre de 500 mg
- Marketing authorisation holder
- ABBVIE DEUTSCHLAND (ALLEMAGNE)
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 24 May 2017
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Prescribed by a hospital doctor
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
65987568CIP75502460CIP133400955024606Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| DALBAVANCINEpoudre | 500 mg · un flacon | FT |
| CHLORHYDRATE DE DALBAVANCINEpoudre | 516 mg · un flacon | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.